Date: Tuesday 04 Sep 2012
LONDON (ShareCast) - Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554.
The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a rapid widening of the airways, greater than a 15% increase in FEV1 (forced expiratory volume at 1 second). This magnitude of what medical professionals call a bronchodilator response was significantly larger than that produced by placebo and appeared to be at least equivalent to that produced by a standard dose of the industry-standard bronchodilator product in these patients. In addition, inhalation of the doses was well tolerated and did not cause any significant adverse effects.
Image Scan, which provides two-dimensional and three-dimensional scanning gizmos to the security and industrial inspection markets, has landed a new industrial inspection system contract worth £138,000.
Health-care software firm Avia has been given a vote of confidence by sector peer Advanced Computer Software Group (ACS), which is lending Avia £350,000 over three years at zero interest. ACS will have the option to convert the loan into a 29.9% stake in Avia, and has also been given the right to nominate a non-executive director to the Avia board. The funds will alleviate the working capital constraints Avia is currently experiencing.
JH
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1.20p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 2.35p |
52 Week Low | 1.10p |
Volume | 0 |
Shares Issued | 136.85m |
Market Cap | £1.64m |
RiskGrade | 320 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
You are here: research